Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program
Management to Host Conference Call Today at 8:30 a.m. ET
View HTML
Toggle Summary NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802
AMES, Iowa , July 27, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced first patient dosed in the Phase 1 study of NLG802 , a novel prodrug of indoximod.  NLG802 is an investigational agent targeting the IDO pathway and represents an important step in the
View HTML
Toggle Summary NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs
AMES, Iowa , July 10, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it has received a Notice of Allowance for U.S. patent application number 15/171,031 from the United States Patent and Trademark Office (USPTO) covering claims to the salts and prodrugs of
View HTML
Toggle Summary NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference Call on July 28, 2017
AMES, Iowa , July 07, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK), today announced that it will release its second quarter 2017 financial results on Friday, July 28, 2017. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to
View HTML
Toggle Summary NewLink Genetics to Regain Rights to GDC-0919
Management to Host Conference Call Thursday, June 8 at 8:30 am ET
View HTML
Toggle Summary NewLink Genetics' Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival (rPFS) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) in Phase 2 Trial
AMES, Iowa , June 05, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announces the presentation of results from a randomized Phase 2 investigator initiated study with indoximod in combination with the therapeutic cancer vaccine, PROVENGE (sipuleucel-T), for patients with
View HTML
Toggle Summary Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer
AMES, Iowa , June 02, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the results from a Phase 2 trial of indoximod in combination with taxane chemotherapy for patients with metastatic breast cancer.    Top line data from the study show that the trial did not
View HTML
Toggle Summary Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
AMES, Iowa , May 18, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that an abstract describing data from a clinical study of its IDO pathway inhibitor, indoximod, in combination with chemotherapeutic agents for patients with newly diagnosed acute myelogenous
View HTML
Toggle Summary Data from Clinical Studies of NewLink Genetics' Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
AMES, Iowa , May 17, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two clinical studies of its IDO pathway inhibitors, indoximod and navoximod (GDC-0919), used in combination with other agents, are now available on the website of the 2017
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conferences
AMES, Iowa , May 08, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation  (NASDAQ:NLNK) today announced that it will participate in the following upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference on May 18 in Las Vegas, NV Jefferies 2017 Global Healthcare
View HTML